Michelson Diagnostics, an Orpington, UK-based medical device company, raised €2.5m in its first tranche of its Series B funding.
The company, which is in discussions with other investors regarding the Second £1.5m Tranche of Series B round expected to close in the coming months, will use the funds to expand its commercial presence in Germany; launch its VivoSight OCT tissue-imaging system; complete the ongoing US multi-centre clinical biopsy avoidance study and explore further applications of the VivoSight system in areas such as wound care and dentistry.
Founded in 2006 and led by Brian Howlett, Chairman, Michelson Diagnostics develops, manufactures and markets the VivoSight multi-beam Optical Coherence Tomography (OCT) scanner, a point-of-care, real-time tissue imaging device. The patented technology, which has CE/TGA regulatory-clearance and FDA 510(k) approval in the United States, provides clinicians with continuous images of the epidermis and superficial dermis of the skin that can be interpreted by a medical professional.
The company has 18 employees and offices in Germany and USA.